Oral Proteins and Peptides Market Know the Scope and Trends

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Oral Proteins and Peptides Market"-, By Type of Target Disease Indication (Acromegaly, Celiac Disease, Chronic Idiopathic Constipation, Enteric Hyperoxaluria, Inflammatory Bowel Disease, and Type II Diabetes), Type of Molecule (Protein and Peptide), Type of Biological Target (GC-C, Insulin Receptor, Oxalate and others), Type of Mechanism of Action (Receptor Stimulation, Substrate Degradation and Others), and Global Forecasts, 2024-2031 And Segment Revenue and Forecast To 2031."

The Oral Proteins and Peptides Market is estimated to reach over USD 28.17 billion by 2031, exhibiting a CAGR of 20.3% during the forecast period.

Request for Sample Pages:
https://www.insightaceanalytic.com/request-sample/2868

Proteins and peptides, essential building blocks of life, hold immense potential in the treatment of various diseases. Over the past three decades, and particularly in recent years, the development of therapeutic proteins has progressed significantly, resulting in a substantial increase in the availability of protein-based medications. However, the oral bioavailability of these molecules remains a major challenge due to their intricate tertiary structure and complex spatial conformation, which render them highly susceptible to degradation within the gastrointestinal (GI) tract.

To overcome this limitation, advancements in peptide formulation technologies are expected to improve oral absorption, thereby increasing the efficacy of oral peptide-based therapies. Notably, promising therapeutic peptides such as Octreotide (developed using Peptelligence technology) and oral Semaglutide (utilizing Eligen technology) have successfully progressed to clinical trials, demonstrating the feasibility of oral peptide delivery.

List of Prominent Players in the Oral Proteins and Peptides Market:
• AstraZeneca
• Biocon Chiasma
• Novo Nordisk A/S
• Allergan
• Oramed Pharmaceuticals
• Proxima Concepts
• Synergy Pharmaceuticals
• Tarsa Therapeutics
• Sanofi
• F. Hoffmann-La Roche Ltd
• Novo Nordisk A/S
• Abbvie Inc.
• Pfizer Inc.
• Bausch Health Companies Inc.
• Chiesi Farmaceutici S.P.A.
• Acadia Pharmaceuticals Inc.
• Aurinia Pharmaceuticals Inc.
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Swk Holdings
• R-Pharm Jsc
• Entera Bio Ltd.
• Proxima Concepts
• Astrazeneca Plc
• Regor Therapeutics Group
• Terns Pharmaceuticals, Inc.
• Structure Therapeutics
• Viking Therapeutics
• Protagonist Therapeutics Inc.
• Rani Therapeutics
• Carmot Therapeutics, Inc.
• Zealand Pharma
• Sciwind Biosciences Co., Ltd.
• Jiangsu Hengrui Pharmaceuticals Co., Ltd

Market Dynamics:
Drivers:
Advancements in nanoparticle carriers, enteric coatings, and enzyme inhibitors have significantly enhanced the stability and bioavailability of proteins and peptides, making oral delivery a viable alternative to traditional injection-based therapies. The growing prevalence of chronic diseases, including diabetes, cancer, and hormonal disorders, has driven the demand for effective and patient-centric treatment solutions. Regulatory authorities such as the FDA have been actively approving novel oral protein and peptide therapies, fostering industry confidence and stimulating further investments in drug development. As a non-invasive alternative to injectable treatments, oral formulations-such as those under development for insulin and other peptide-based therapies-offer improved patient compliance and quality of life.

Curious about this latest version of the report? @ https://www.insightaceanalytic.com/enquiry-before-buying/2868

Challenges:
The development of stable and effective oral formulations of proteins and peptides presents significant technical hurdles. The requirement for advanced formulation technologies, such as encapsulation and molecular modification strategies, increases research and development costs as well as drug development timelines. A primary barrier to commercialization is the low bioavailability of oral proteins and peptides due to degradation by gastrointestinal enzymes and the acidic environment of the stomach.

Regional Trends:
North America is expected to maintain the largest market share throughout the forecast period, driven by robust research and development efforts and substantial investments from biotechnology and pharmaceutical companies in innovative peptide therapies. Additionally, favorable regulatory frameworks, including Fast Track and Breakthrough Therapy Designations, enable accelerated approval pathways, expediting market entry for new oral peptide treatments. Meanwhile, the Asia-Pacific region is projected to exhibit the highest growth rate, fueled by increasing healthcare expenditures, a rising patient population, and growing awareness of peptide-based therapies. Efforts to streamline regulatory approvals in emerging markets are further facilitating the rapid commercialization of innovative therapies.

Recent Developments:
• In June 2023, Pfizer Inc. declared its intention to proceed with the clinical development of a single oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate for the possible treatment of people with Type 2 diabetes mellitus (T2DM) and obesity. Subject to the outcomes of the ongoing Phase 2 trial, the company will proceed with the clinical development of lotiglipron (PF-07081532) and continue to advance the clinical program for danuglipron (PF-06882961). The business is working on a once-daily modified release version of danuglipron and anticipates having preparations for the late-stage program finalized by the end of 2023.
• In August 2023, Entera Bio, presented abstracts at the annual conference of the American Society for Bone and Mineral Research (ASBMR) on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the treatment of postmenopausal women at high risk of fracture.

For More Customization @ https://www.insightaceanalytic.com/customisation/2868

Segmentation of Oral Proteins and Peptides Market.
Global Oral Proteins and Peptides Market- Type of Target Disease Indication
• Acromegaly
• Celiac Disease
• Chronic Idiopathic Constipation
• Enteric Hyperoxaluria
• Inflammatory Bowel Disease
• Type II Diabetes
Global Oral Proteins and Peptides Market - Type of Molecule
• Protein
• Peptide
Global Oral Proteins and Peptides Market - Type of Biological Target
• GC-C
• Insulin Receptor
• Oxalate
• Others
Global Oral Proteins and Peptides Market - Type of Mechanism of Action
• Receptor Stimulation
• Substrate Degradation
• Others
Global Oral Proteins and Peptides Market - By Region
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Get more information:
https://www.insightaceanalytic.com/report/oral-proteins-and-peptides-market/2868

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.https://www.insightaceanalytic.com/images_data/148861653.JPG

Contact us:
info@insightaceanalytic.com
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ
Twitter: https://twitter.com/Insightace

This release was published on openPR.